Skip to search formSkip to main contentSkip to account menu

SB 1518

Known as: SB-1518, SB1518 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1… 
Highly Cited
2012
Highly Cited
2012
PURPOSE The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the… 
Review
2012
Review
2012
JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction… 
Highly Cited
2012
Highly Cited
2012
Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly… 
Highly Cited
2011
Highly Cited
2011
Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2(V617F)), a tyrosine kinase critically involved in receptor… 
Highly Cited
2011
Highly Cited
2011
FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its… 
Highly Cited
2011
Highly Cited
2011
SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase… 
Highly Cited
2011
Highly Cited
2011
Abstract 282 Background: The JAK2V617F mutation has been linked to the pathogenesis of myeloproliferative neoplasia. Pacritinib… 
2011
2011
6515 Background: The JAK2V617F mutant enzyme has been linked to the pathogenesis of myeloproliferative neoplasms. SB1518 is a… 
Highly Cited
2009
Highly Cited
2009
Abstract 3905 Poster Board III-841 Mutation of Janus Associated Kinase 2 (JAK2) at amino acid 617 and the resulting…